178 related articles for article (PubMed ID: 11436111)
1. Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
Carlson LE; Koski T; Glück S
Bone Marrow Transplant; 2001 May; 27(9):989-98. PubMed ID: 11436111
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation.
Conner-Spady BL; Cumming C; Nabholtz JM; Jacobs P; Stewart D
Bone Marrow Transplant; 2005 Aug; 36(3):251-9. PubMed ID: 15937502
[TBL] [Abstract][Full Text] [Related]
4. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
Schmid P; Schippinger W; Nitsch T; Huebner G; Heilmann V; Schultze W; Hausmaninger H; Wischnewsky M; Possinger K
J Clin Oncol; 2005 Jan; 23(3):432-40. PubMed ID: 15659490
[TBL] [Abstract][Full Text] [Related]
5. The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation.
Hjermstad MJ; Loge JH; Evensen SA; Kvaløy SO; Fayers PM; Kaasa S
Bone Marrow Transplant; 1999 Dec; 24(11):1219-28. PubMed ID: 10642812
[TBL] [Abstract][Full Text] [Related]
6. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer.
Rahman Z; Kavanagh J; Champlin R; Giles R; Hanania E; Fu S; Zu Z; Mehra R; Holmes F; Kudelka A; Claxton D; Verschraegen C; Gajewski J; Andreeff M; Heimfeld S; Berenson R; Ellerson D; Calvert L; Mechetner E; Holzmayer T; Dayne A; Hamer J; Bachier C; Ostrove J; Deisseroth A
Clin Cancer Res; 1998 Nov; 4(11):2717-21. PubMed ID: 9829734
[TBL] [Abstract][Full Text] [Related]
8. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
[TBL] [Abstract][Full Text] [Related]
9. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.
Bewick M; Conlon M; Gerard S; Lee H; Parissenti AM; Zhang L; Glück S; Lafrenie RM
Bone Marrow Transplant; 2001 Apr; 27(8):847-53. PubMed ID: 11477443
[TBL] [Abstract][Full Text] [Related]
10. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
Winer EP; Lindley C; Hardee M; Sawyer WT; Brunatti C; Borstelmann NA; Peters W
Psychooncology; 1999; 8(2):167-76. PubMed ID: 10335560
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
[TBL] [Abstract][Full Text] [Related]
14. Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma.
Zia MI; Forsyth P; Chaudhry A; Russell J; Stewart DA
Bone Marrow Transplant; 2002 Nov; 30(9):565-9. PubMed ID: 12407430
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
Stemmler HJ; Salat C; Lindhofer H; Menzel H; Untch M; Kahlert S; Konecny G; Sauer H; Ledderose G; Heinemann V; Kolb HJ
Anticancer Res; 2005; 25(4):3047-54. PubMed ID: 16080564
[TBL] [Abstract][Full Text] [Related]
16. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S
Breast J; 2006; 12(6):531-5. PubMed ID: 17238982
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy.
Vredenburgh JJ; Madan B; Coniglio D; Ross M; Broadwater G; Niedzwiecki D; Edwards J; Marks L; Vandemark R; McDonald C; Affronti ML; Peters WP
Bone Marrow Transplant; 2006 Jun; 37(11):1009-15. PubMed ID: 16633363
[TBL] [Abstract][Full Text] [Related]
19. Anxiety and quality of life of women who receive radiation or chemotherapy for breast cancer.
Schreier AM; Williams SA
Oncol Nurs Forum; 2004; 31(1):127-30. PubMed ID: 14722597
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation.
Hjermstad MJ; Knobel H; Brinch L; Fayers PM; Loge JH; Holte H; Kaasa S
Bone Marrow Transplant; 2004 Aug; 34(3):257-66. PubMed ID: 15170167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
